TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma (TARGET-HCC)

TheraBionic P1 Device for Patients With Advanced Hepatocellular Carcinoma (HCC) Who Fail First and Second Line Therapy

The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced hepatocellular carcinoma (HCC) who have no standard of care options can affect patients survival. The main questions it aims to answer are:

• will the TheraBionic P1 device affect overall survival in advance HCC
• the long term safety and tolerability of the TheraBionic P1 device
• assessment of how the disease responded to the TheraBionic P1 device

Study Overview

• Status: Recruiting
• Conditions: Hepatocellular Carcinoma Recurrent
• Intervention / Treatment: Device: TheraBionic P1

• Study Type: Interventional
• Enrollment (Estimated): 198
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Anthony F Shields, M.D.; Phone Number: 313-576-8735; Email: shieldsa@karmanos.org

Study Locations

• United States
  • Michigan
    • Bay City, Michigan, United States, 48706
      • Recruiting
      • Karmanos Cancer Institute at McLaren Bay Region
      • Contact: Phone Number: 1-989-667-2370
    • Detroit, Michigan, United States, 48201
      • Recruiting
      • Karmanos Cancer Institute
      • Contact: Anthonly F Shields, M.D.; Phone Number: 313-576-8735; Email: shieldsa@karmanos.org
    • Flint, Michigan, United States, 48532
      • Recruiting
      • Karmanos Cancer Institute at McLaren Flint
      • Contact: Phone Number: 1-810-342-3800
    • Lansing, Michigan, United States, 48910
      • Recruiting
      • Karmanos Cancer Institute at McLaren Greater Lansing
      • Contact: Phone Number: 1-517-975-9500
    • Lapeer, Michigan, United States, 48446
      • Recruiting
      • Karmanos Cancer Institute at McLaren Lapeer Region
      • Contact: Phone Number: 810-667-4994
    • Mount Pleasant, Michigan, United States, 48858
      • Recruiting
      • Karmanos Cancer Institute at McLaren Central Michigan, Morey Cancer Center
      • Contact: Phone Number: 1-989-772-6811

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients with advanced hepatocellular carcinoma (HCC) (defined as a liver tumor not eligible for local therapies given the extent of disease or a livor tumor that recurred after local therapy)
• Patients who have failed at least two lines of therapy* or who are no longer eligible for any line of standard therapy or who are intolerant to at least two lines of therapy.
• Patients with evaluable disease
• Patients must be ≥ 22 years old and must be able to understand and sign an informed consent.
• Female patients of childbearing potential and their partners and male patients must agree to use adequate contraception during the period of study treatment.
• Patients with a life expectancy of at least 3 months

Exclusion Criteria:

• Patients with known active secondary malignancy, unless, in the opinion of the investigator, it is unlikely to interfere with the safety and efficacy of the endpoints
• Patients taking any other investigational drugs
• Patients with active oral mucosal inflammation, ulceration, or other pathology that could interfere with the use of the device
• Patients receiving calcium channel blockers and any agent blocking L-type of T-type Voltage Gated Calcium Channels, e.g., amlodipine, nifedipine, ethosuximide, ascorbic acid (vitamin C), etc. unless their medical treatment is discontinued to prior to treatment on study. Patients must agree to abstain from using calcium channel blockers and any agent blocking L-type or T-type voltage gated calcium channels for the duration of treatment on study.
• Patients who are breastfeeding. If a breastfeeding participant would like to be part of this study, breastfeeding must be discontinued.
• Patients that do not agree to be followed according to the study protocol or have cognitive or physical inability to use the device for the prescribed period and frequency (three 60-minute treatments in the morning, middle of the day, and evening)
• Patients with a known severe (e.g., anaphylactic) allergy to nickel

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: TheraBionic P1 device; Self administered Amplitude-modulated electromagnetic fields three times daily	Device: TheraBionic P1; Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three 60-minute treatments per day, administered in the morning, middle of the day, and in the evening

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival	Overall survival assessment will be recorded in days and will represent the period starting at the date of treatment initiation and finishing at the date of patient death from any cause. Living patients at the time of analysis will have the date of last contact (consultation visit or phone contact) used to define overall survival	From start of treatment until death, up to 24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PROMIS Measures of Pain Interference	National Institutes of Health Patient Reported Outcome Measurement Information System (PROMIS) measures of Pain Interference short form 4a. PROMIS scores can range from 0 to 100; scales are calibrated using a T-score metric with a mean of 50 and standard deviation of 10. A higher score indicates more pain interference (poorer health). 4 items	From Start of Treatment to the end of treatment up to 12 months
Patient-reported outcomes (PRO)	Patient-reported outcomes (PRO) measures will assess the trajectory of patient rated tolerability of treatment (Functional Assessment of Cancer Therapy items regarding bother of side effects, one item), patient-rated symptomatic adverse events (11 Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events item library items)	From Start of Treatment to the end of treatment up to 12 months
PROMIS Measures of Pain Intensity	NIH Patient Reported Outcome Measurement Information System (PROMIS) measures of Pain Intensity short form 1a. PROMIS scores can range from 0 to 100; scales are calibrated using a T-score metric with a mean of 50 and standard deviation of 10. A higher score indicates more pain intensity (poorer health). 1 item	From Start of Treatment to the end of treatment up to 12 months
ECOG Performance Status	(ECOG)Eastern Cooperative Oncology Group performance status scale to measure functional status and ability to carry out activities of daily living. A system used to assess how a patient's cancer or other serious illness affects their daily living abilities. It's a 6-point scale (0-5) where lower scores indicate better function and higher scores indicate more limitations	From Start of Treatment to the end of treatment up to 12 months
Disease Control Rate	Disease control will be defined as the percentage of patients who are alive and have documented response status of complete response (CR), partial response (PR) or stable disease (SD) at 4 months and 6 months from the date of enrollment.	From enrollment up to 6 months
Duration of overall response	Measured from the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded on study). The duration of overall complete response is measured from the time measurement criteria are first met for CR until the first date that recurrent disease is objectively documented. Duration of stable disease: Stable disease is measured from the start of the treatment until the criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started	From start of treatment up to 24 months
Time to Progression (TTP)	Time-to-radiological progression assessment will be recorded in days and will represent the period starting at the date of treatment initiation and finishing at the date of radiological assessment documenting tumor progression. Patients who initiate post-study anticancer therapy or die without documented progression will be censored at that time point.	Start of treatment to death from any cause up to 24 months
Progression-free survival (PFS)	Progression-free survival assessment will be recorded in days and will represent the period starting at the date of treatment initiation and finishing at the later of the date of documentation of radiologic tumor progression, date of last follow-up on study treatment or death, whichever comes first. Patients who initiate post-study antitumor therapy prior to radiologic progression will be censored for PFS at that date.	Start of treatment to progression of disease, last follow-up on study or death, whichever comes first up to 24 months
PROMIS Measures of Physical Function	National Institutes of Health Patient Reported Outcome Measurement Information System (PROMIS) measures of physical function short form 4a. PROMIS scores can range from 0 to 100; scales are calibrated using a T-score metric with a mean of 50 and standard deviation of 10. A higher score indicates less physical function (poorer health). 4 items	From Start of Treatment to the end of treatment up to 12 months

Collaborators and Investigators

• Sponsor: Barbara Ann Karmanos Cancer Institute
• Collaborators: THERABIONIC INC.
• Investigators: Principal Investigator: Anthony F Shields, M.D., Wayne State University

Study record dates

Study Major Dates

• Study Start (Actual): October 20, 2025
• Primary Completion (Estimated): August 31, 2028
• Study Completion (Estimated): August 31, 2028

Study Registration Dates

• First Submitted: August 5, 2025
• First Submitted That Met QC Criteria: August 5, 2025
• First Posted (Actual): August 12, 2025

Study Record Updates

• Last Update Posted (Actual): April 13, 2026
• Last Update Submitted That Met QC Criteria: April 7, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Neoplasms by Histologic Type; Digestive System Neoplasms; Digestive System Diseases; Liver Diseases; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Liver Neoplasms; Carcinoma; Carcinoma, Hepatocellular
• Other Study ID Numbers: 2024-074; AM-001 (TheraBionic); TR79005KCI00019 (Other Grant/Funding Number: U Can-Cer Vive)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No